Beloren | Updates

By Sven Schimansky-Wabra

Beloren reaches 100,000 EUR within 24 hours after campaign launch

Public
Public

Dear Companists,

we are overwhelmed how fast the investment threshold of € 100.000 was overcome together with you. Personally I was also very pleased how fast the numerous inquiries really go into depth and you can see that almost everyone here deals intensively with the topic of generic drugs.

I will take this opportunity to report on the latest events and the next steps. In the contract negotiations with the US partner, it turned out that even in the last few months he has received numerous formulations from the FDA review without a large approval study. And that he himself regularly carries out the French test required by the UK authorities and has a great deal of experience with it.

This confirms that we have the right partner for US at our table and of course it will also affect the costs if such tests do not have to be outsourced.

Currently, we have had American goods brought into German laboratories to prove the equality of the products, which in the end will make our argumentation with the US FDA authority much easier.

We expect the following topics in the coming weeks and will of course keep you up to date.

  • Contract signature with the US Partner
  • FDA appointment confirmation
  • Contract signature with the license partner in Brazil.
  • Confirmation of the remaining 5 EU authorities regarding our formula.
  • Start of negotiations with a Russian partner, which is the next largest for Skinoren after the EU, US, Brazil.

 

Thank you very much for the trust you have placed in us and for your continued good cooperation.

With best regards

Sven Schimansky-Wabra



Comments

Only registered Companists can comment. Please log in to leave a comment.

Note

Investments in crowdfunding projects offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, these investments are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by splitting their investment amount between crowdfunding campaigns rather than investing all of it in one crowdfunding campaign. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the Companists are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the Companists – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, crowdfunding investments are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 598,800

Invested

572

Companists

19.23 %

Share Offered